Cancer-Killing viruses take on solid tumours in new trial
NCT ID NCT02285816
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1/2 trial tests a vaccine made from two viruses designed to target and kill cancer cells that have a specific protein called MAGE-A3. The viruses are given to 56 people with advanced solid tumours that have not responded to other treatments. The goal is to see if the vaccine can shrink tumours and how safe it is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MG1 Maraba/MAGE-A3 virus vaccine (with or without adenovirus priming)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumours that express the MAGE-A3 protein, potentially shrinking tumours and extending life.
What could go wrong
This is an early-phase trial with only 56 participants, so results may not apply to everyone. The treatment may cause side effects or fail to shrink tumours, and it is not yet clear if it works better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada